ABCG2 and malignant colon neoplasm: Similar to our findings, co-treatment with other BCRP/ABCG2 inhibitors also had no effect on erlotinib activity in colon cancer cell lines, which might be due to the fact that erlotinib is not recognized as a typical substrate by BCRP/ABCG2 [31].